Current Report · Items 5.02 · 8-K

Halozyme Therapeutics, Inc.

HALONASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Aug 18, 2026Accepted Aug 18, 2026, 4:04 PM EDTCIK 1159036Accession 0001159036-26-000106

Company context

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Current securities

HALONASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2028 and was not initially assigned to any Board committee. Ms. Appelhans will receive compensation for her services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time. The current components of the non-employee director compensation program were described in our proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026. There are no arrangements or understandings pursuant to which Ms. Appelhans was elected as a director and there are no related person transactions between the Company and Ms. Appelhans.